DK3820894T3 - Mesothelin- og cd137-bindende molekyler - Google Patents
Mesothelin- og cd137-bindende molekylerInfo
- Publication number
- DK3820894T3 DK3820894T3 DK19742323.9T DK19742323T DK3820894T3 DK 3820894 T3 DK3820894 T3 DK 3820894T3 DK 19742323 T DK19742323 T DK 19742323T DK 3820894 T3 DK3820894 T3 DK 3820894T3
- Authority
- DK
- Denmark
- Prior art keywords
- mesothelin
- binding molecules
- molecules
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811450.4A GB201811450D0 (en) | 2018-07-12 | 2018-07-12 | Mesothelin and CD137 binding molecules |
| PCT/EP2019/068817 WO2020011976A1 (en) | 2018-07-12 | 2019-07-12 | Mesothelin and cd137 binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3820894T3 true DK3820894T3 (da) | 2025-06-30 |
Family
ID=63273224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19742323.9T DK3820894T3 (da) | 2018-07-12 | 2019-07-12 | Mesothelin- og cd137-bindende molekyler |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12319739B2 (enExample) |
| EP (1) | EP3820894B1 (enExample) |
| JP (2) | JP7360441B2 (enExample) |
| KR (1) | KR20210030925A (enExample) |
| CN (1) | CN112437776B (enExample) |
| AR (1) | AR115769A1 (enExample) |
| AU (1) | AU2019303081A1 (enExample) |
| BR (1) | BR112021000396A2 (enExample) |
| CA (1) | CA3103173A1 (enExample) |
| DK (1) | DK3820894T3 (enExample) |
| ES (1) | ES3035107T3 (enExample) |
| FI (1) | FI3820894T3 (enExample) |
| GB (1) | GB201811450D0 (enExample) |
| HR (1) | HRP20250872T1 (enExample) |
| HU (1) | HUE072217T2 (enExample) |
| IL (1) | IL280007B2 (enExample) |
| MX (1) | MX2021000397A (enExample) |
| PL (1) | PL3820894T3 (enExample) |
| PT (1) | PT3820894T (enExample) |
| SG (1) | SG11202011960XA (enExample) |
| TW (1) | TWI839365B (enExample) |
| WO (1) | WO2020011976A1 (enExample) |
| ZA (1) | ZA202007570B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3027302A1 (en) | 2016-06-20 | 2017-12-28 | F-Star Beta Limited | Binding members(1) |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
| CA3098374A1 (en) | 2018-04-25 | 2019-10-31 | Prometheus Biosciences, Inc. | Optimized anti-tl1a antibodies |
| GB201811450D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| TWI861005B (zh) | 2018-07-12 | 2024-11-11 | 英商英沃克斯製藥有限公司 | 結合pd-l1及cd137的抗體分子 |
| EP3820898B1 (en) | 2018-07-12 | 2025-09-03 | invoX Pharma Limited | Antibody molecules that bind cd137 and ox40 |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| WO2020081895A2 (en) * | 2018-10-18 | 2020-04-23 | The Scripps Research Institute | Siv envelope trimer |
| CA3158638A1 (en) | 2019-10-24 | 2021-04-29 | Prometheus Biosciences, Inc. | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| EP4573118A2 (en) * | 2022-08-15 | 2025-06-25 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
| US20250340667A1 (en) | 2022-08-26 | 2025-11-06 | Merck Patent Gmbh | Cancer Treatment comprising an anti-MSLN/CD137 antibody and a chemotherapeutic |
| WO2024042104A1 (en) | 2022-08-26 | 2024-02-29 | Merck Patent Gmbh | Combination cancer treatment comprising an anti-msln/cd137 antibody and pd-1/pd-l1 inhibitor |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2245404C3 (de) | 1972-09-15 | 1978-08-31 | Robert Bosch Gmbh, 7000 Stuttgart | Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben |
| JPS531908B2 (enExample) | 1973-11-12 | 1978-01-23 | ||
| JPS5746634B2 (enExample) | 1974-05-10 | 1982-10-04 | ||
| JPS5146628A (ja) | 1974-10-17 | 1976-04-21 | Nippon Denso Co | Teikoirisupaakupuragu |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| AU760120B2 (en) | 1997-12-01 | 2003-05-08 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Antibodies, including Fv molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| DE19818214A1 (de) | 1998-04-24 | 1999-10-28 | Bosch Gmbh Robert | Zündkerze für eine Brennkraftmaschine |
| EP1180123B1 (en) | 1999-05-27 | 2008-07-16 | Government of the United States as represented by the Secretary, Department of Health and Human Services | Immunoconjugates having high binding affinity |
| EP1272647B1 (en) | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| JP4578025B2 (ja) | 2001-07-06 | 2010-11-10 | 日本特殊陶業株式会社 | スパークプラグ |
| JP2003228556A (ja) | 2002-02-01 | 2003-08-15 | Casio Comput Co Ltd | 文書ファイル処理装置及びプログラム |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| KR101404512B1 (ko) | 2005-01-05 | 2015-01-29 | 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. | 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을갖는 합성 면역글로불린 영역 |
| EP1851244A4 (en) | 2005-02-15 | 2009-04-15 | Gtc Biotherapeutics Inc | ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF |
| JP4949373B2 (ja) | 2005-03-10 | 2012-06-06 | モルフォテック、インク． | 抗メソテリン抗体 |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| GB0624500D0 (en) | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| ES2975748T3 (es) | 2007-06-26 | 2024-07-12 | F Star Therapeutics Ltd | Presentación de agentes de unión |
| EP3103814A1 (en) | 2007-11-26 | 2016-12-14 | Bayer Intellectual Property GmbH | Anti-mesothelin antibodies and uses therefor |
| MX2010006466A (es) | 2007-12-14 | 2010-09-28 | Bristol Myers Squibb Co | Moleculas de union al receptor ox40 de humano. |
| AU2009234277B2 (en) | 2008-04-11 | 2014-12-04 | Aptevo Research And Development Llc | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP2358390A1 (en) | 2008-11-13 | 2011-08-24 | Emergent Product Development Seattle, LLC | Cd37 immunotherapeutic combination therapies and uses thereof |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| CA2756393C (en) | 2009-03-24 | 2017-06-20 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-mesothelin antibodies |
| UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| RU2551963C2 (ru) | 2010-09-09 | 2015-06-10 | Пфайзер Инк. | Молекулы, связывающиеся с 4-1вв |
| TWI589589B (zh) | 2010-12-20 | 2017-07-01 | 建南德克公司 | 抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物 |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR102163408B1 (ko) | 2012-05-31 | 2020-10-08 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| JP5276742B1 (ja) | 2012-08-09 | 2013-08-28 | 日本特殊陶業株式会社 | 点火プラグ |
| EP2900695B1 (en) | 2012-09-27 | 2018-01-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| HUE043903T2 (hu) | 2012-12-03 | 2019-09-30 | Bristol Myers Squibb Co | Immunmodulációs FC fúziós proteinek rákellenes aktivitásának javítása |
| IL240838B (en) | 2013-03-15 | 2022-09-01 | Glaxosmithkline Ip Dev Ltd | Anti-3–lag binding proteins |
| WO2014151910A1 (en) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| GB201317622D0 (en) | 2013-10-04 | 2013-11-20 | Star Biotechnology Ltd F | Cancer biomarkers and uses thereof |
| US10899840B2 (en) | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| UY36032A (es) | 2014-03-14 | 2015-10-30 | Novartis Ag | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas |
| US20150307620A1 (en) | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| WO2015198312A1 (en) | 2014-06-24 | 2015-12-30 | Ccam Therapeutics Ltd. | Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy |
| JP5902757B2 (ja) | 2014-06-24 | 2016-04-13 | 日本特殊陶業株式会社 | スパークプラグ |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| US9407069B2 (en) | 2014-08-10 | 2016-08-02 | Federal-Mogul Ignition Company | Spark plug with improved seal |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| PT3242890T (pt) | 2015-01-08 | 2019-12-10 | Genmab As | Agentes de ligação agonistas do recetor de tnf |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| TW201632559A (zh) | 2015-02-22 | 2016-09-16 | 索倫多醫療公司 | 結合ｃｄ１３７之抗體治療劑 |
| TW201642897A (zh) | 2015-04-08 | 2016-12-16 | Ｆ 星生物科技有限公司 | Ｈｅｒ２結合劑治療 |
| RU2727165C2 (ru) | 2015-05-04 | 2020-07-21 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
| IL255767B2 (en) | 2015-05-21 | 2024-04-01 | Alligator Bioscience Ab | Novel polypeptides |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| JP6025921B1 (ja) | 2015-06-22 | 2016-11-16 | 日本特殊陶業株式会社 | スパークプラグ |
| CN108348573A (zh) | 2015-07-15 | 2018-07-31 | 皮里斯制药有限公司 | Lag-3特异性的新型蛋白 |
| CN108348601B (zh) | 2015-07-22 | 2022-05-17 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
| SMT202100527T1 (it) | 2015-07-30 | 2021-11-12 | Macrogenics Inc | Molecole di legame a pd-1 e lag-3 e loro metodi d'uso |
| EA201890456A1 (ru) | 2015-08-07 | 2018-07-31 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Новый слитый полипептид, специфичный в отношении lag-3 и pd-1 |
| ES2802994T3 (es) | 2015-09-22 | 2021-01-22 | Dingfu Biotarget Co Ltd | Anticuerpo completamente humano contra CD137 humano y uso del mismo |
| KR101782487B1 (ko) | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| MY198560A (en) | 2015-10-02 | 2023-09-05 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| KR102220275B1 (ko) | 2015-11-18 | 2021-02-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
| US20190330336A1 (en) | 2015-11-19 | 2019-10-31 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
| IL304871A (en) | 2016-01-11 | 2023-10-01 | Inhibrx Inc | Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses |
| JP6365802B2 (ja) | 2016-03-18 | 2018-08-01 | 大日本印刷株式会社 | 中間転写媒体と熱転写シートとの組合せ、及び印画物の形成方法 |
| US20190169308A1 (en) * | 2016-04-22 | 2019-06-06 | Alligator Bioscience Ab | Novel bispecific polypeptides against cd137 |
| IL321475A (en) | 2016-05-06 | 2025-08-01 | Medimmune Llc | Bispecific binding proteins and their uses |
| TW201806972A (zh) * | 2016-05-27 | 2018-03-01 | 美商艾伯維生物醫療股份有限公司 | 雙特異性結合蛋白 |
| US20190106494A1 (en) | 2016-06-13 | 2019-04-11 | Askgene Pharma Inc. | PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CA3027302A1 (en) | 2016-06-20 | 2017-12-28 | F-Star Beta Limited | Binding members(1) |
| CN107523546A (zh) | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的nk细胞及其用途 |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| AU2017283181B2 (en) | 2016-06-20 | 2024-08-15 | F-Star Therapeutics Limited | Binding molecules binding PD-L1 and LAG-3 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| WO2018017673A1 (en) | 2016-07-20 | 2018-01-25 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 |
| UA127449C2 (uk) | 2016-09-23 | 2023-08-30 | Мерус Н.В. | Зв'язувальна молекула, яка модулює біологічну активність, що експресується клітиною |
| GB201616699D0 (en) | 2016-09-30 | 2016-11-16 | Mab Designs Ltd | Antibodies |
| GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| WO2018115859A1 (en) | 2016-12-20 | 2018-06-28 | Kymab Limited | Multispecific antibody with combination therapy for immuno-oncology |
| GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
| CA3065008A1 (en) | 2017-05-26 | 2018-11-29 | Novimmune Sa | Anti-cd47 x anti-mesothelin antibodies and methods of use thereof |
| WO2018222711A2 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| KR20250020679A (ko) | 2017-08-04 | 2025-02-11 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
| US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
| WO2019121906A1 (en) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Specific pd-l1 binding sequences inserted in a ch3 domain |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| EP3820898B1 (en) | 2018-07-12 | 2025-09-03 | invoX Pharma Limited | Antibody molecules that bind cd137 and ox40 |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811450D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| TWI861005B (zh) | 2018-07-12 | 2024-11-11 | 英商英沃克斯製藥有限公司 | 結合pd-l1及cd137的抗體分子 |
| BR112021022831A2 (pt) | 2019-05-14 | 2022-01-18 | F Star Therapeutics Ltd | Regimes de dosagem para a administração de um anticorpo biespecífico lag-3/pd-l1 |
-
2018
- 2018-07-12 GB GBGB1811450.4A patent/GB201811450D0/en not_active Ceased
-
2019
- 2019-07-12 AU AU2019303081A patent/AU2019303081A1/en active Pending
- 2019-07-12 AR ARP190101973A patent/AR115769A1/es unknown
- 2019-07-12 IL IL280007A patent/IL280007B2/en unknown
- 2019-07-12 PL PL19742323.9T patent/PL3820894T3/pl unknown
- 2019-07-12 ES ES19742323T patent/ES3035107T3/es active Active
- 2019-07-12 FI FIEP19742323.9T patent/FI3820894T3/fi active
- 2019-07-12 SG SG11202011960XA patent/SG11202011960XA/en unknown
- 2019-07-12 CN CN201980046873.7A patent/CN112437776B/zh active Active
- 2019-07-12 PT PT197423239T patent/PT3820894T/pt unknown
- 2019-07-12 DK DK19742323.9T patent/DK3820894T3/da active
- 2019-07-12 MX MX2021000397A patent/MX2021000397A/es unknown
- 2019-07-12 CA CA3103173A patent/CA3103173A1/en active Pending
- 2019-07-12 TW TW108124775A patent/TWI839365B/zh active
- 2019-07-12 HU HUE19742323A patent/HUE072217T2/hu unknown
- 2019-07-12 US US17/259,634 patent/US12319739B2/en active Active
- 2019-07-12 HR HRP20250872TT patent/HRP20250872T1/hr unknown
- 2019-07-12 KR KR1020217000265A patent/KR20210030925A/ko active Pending
- 2019-07-12 JP JP2021500386A patent/JP7360441B2/ja active Active
- 2019-07-12 EP EP19742323.9A patent/EP3820894B1/en active Active
- 2019-07-12 BR BR112021000396-7A patent/BR112021000396A2/pt unknown
- 2019-07-12 WO PCT/EP2019/068817 patent/WO2020011976A1/en not_active Ceased
-
2020
- 2020-12-04 ZA ZA2020/07570A patent/ZA202007570B/en unknown
-
2023
- 2023-09-29 JP JP2023169048A patent/JP2023178323A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR115769A1 (es) | 2021-02-24 |
| IL280007B2 (en) | 2025-05-01 |
| CN112437776B (zh) | 2024-07-26 |
| TW202012448A (zh) | 2020-04-01 |
| GB201811450D0 (en) | 2018-08-29 |
| KR20210030925A (ko) | 2021-03-18 |
| CN112437776A (zh) | 2021-03-02 |
| WO2020011976A1 (en) | 2020-01-16 |
| EP3820894A1 (en) | 2021-05-19 |
| FI3820894T3 (fi) | 2025-07-03 |
| HUE072217T2 (hu) | 2025-11-28 |
| IL280007A (en) | 2021-03-01 |
| SG11202011960XA (en) | 2020-12-30 |
| HRP20250872T1 (hr) | 2025-09-26 |
| US20210309753A1 (en) | 2021-10-07 |
| ZA202007570B (en) | 2025-09-25 |
| PT3820894T (pt) | 2025-07-02 |
| US12319739B2 (en) | 2025-06-03 |
| MX2021000397A (es) | 2021-05-27 |
| JP7360441B2 (ja) | 2023-10-12 |
| TWI839365B (zh) | 2024-04-21 |
| EP3820894B1 (en) | 2025-05-07 |
| ES3035107T3 (en) | 2025-08-28 |
| CA3103173A1 (en) | 2020-01-16 |
| JP2021524269A (ja) | 2021-09-13 |
| BR112021000396A2 (pt) | 2021-04-06 |
| AU2019303081A1 (en) | 2021-03-11 |
| JP2023178323A (ja) | 2023-12-14 |
| IL280007B1 (en) | 2025-01-01 |
| PL3820894T3 (pl) | 2025-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3820894T3 (da) | Mesothelin- og cd137-bindende molekyler | |
| IL281568A (en) | Collagen-localized immunomodulatory molecules and methods thereof | |
| IL269534A (en) | Chimeric molecules and uses thereof | |
| EP3759143A4 (en) | ANTI-TIGIT ANTIBODIES AND THEIR USES | |
| EP3740224A4 (en) | ANTI-LILRB ANTIBODIES AND THEIR USES | |
| IL262095A (en) | Anti-pacap antibodies and uses thereof | |
| DK3625263T3 (da) | Anti-galectin- 9-antistoffer og anvendelser deraf | |
| DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
| DK3365368T3 (da) | Tgfbeta1-bindende immunoglobuliner og anvendelse deraf | |
| EP3504243A4 (en) | ANTI-TIM-3 ANTIBODIES AND USES THEREOF | |
| DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
| PL3380522T3 (pl) | Cząsteczki przeciwciał wobec april i ich zastosowania | |
| DK3532499T3 (da) | ANTI-IL-33-antistoffer og anvendelser deraf | |
| IL278122B1 (en) | Pteridinone compounds and uses thereof | |
| EP3735427A4 (en) | ANTI-MCT1 ANTIBODIES AND ASSOCIATED USES | |
| DK3402821T5 (da) | Psma-bindende antistof og anvendelser deraf | |
| EP3904382A4 (en) | ANTI-IL-23P19 ANTIBODIES AND ITS USES | |
| EP3893945A4 (en) | CROMOGLYC ESTERS AND THEIR USES | |
| EP3580241A4 (en) | ANTI-FACTOR D ANTIBODIES AND USES OF THESE LATEST | |
| DK3490988T3 (da) | Ny forbindelse og fremgangsmåde | |
| IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
| IL271398A (en) | Anti-l1-cam antibodies and uses thereof | |
| EP3615084A4 (en) | ACTIVE MOLECULES IN A MEMBRANE | |
| EP3781213A4 (en) | TRANS-SPLICE MOLECULES | |
| DK3417058T3 (da) | Sortase-modificerede molekyler og anvendelser deraf |